Form 10-Q · Quarterly report
Quest Diagnostics 10-Q, filed Oct 23, 2026
- Filed
- CIK
- 0001022079
- Accession no.
- 0001022079-26-000108
Summary
Quest Diagnostics reported third-quarter 2026 net revenues of $3.097 billion, up 10.0% from a year earlier, with net income attributable to the company of $312 million and diluted earnings per share of $2.78. DIS volume rose 14.5%, helped by new relationships with Corewell Health and increased lab testing at Fresenius Medical Care dialysis clinics in the United States.
Key points
- Total net revenues for the quarter were $3.097 billion, compared with $2.816 billion a year earlier.
- Net income attributable to Quest Diagnostics was $312 million and diluted EPS was $2.78, compared with $245 million and $2.16 a year earlier.
- DIS volume increased 14.5%, including 9.5 percentage points from new Corewell Health relationships and increased testing at Fresenius Medical Care dialysis clinics.
- Revenue per requisition fell 4.2%, mainly on Corewell Health and Fresenius Medical Care business mix; excluding those, it rose 1.7%.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2.Management’s Discussion Results of Operations The following tables set forth certain results of operations data for the periods presented: Three Months Ended September 30, Nine Months Ended September 30, 2026 2025 $ Change % Change 2026 2025 $ Change % Change (dollars in millions, except per share amounts) Net revenues: DIS business $ 3,035 $ 2,755 $ 280 10.2 % $ 8,845 $ 8,043 $ 802 10.0 % DS businesses 62 61 1 2.3 190 186 4 2.5 Total net revenues $ 3,097 $ 2,816 $ 281 10.0 % $ 9,035 $ 8,229 $ 806 9.8 % Operating costs and expenses and other operating income: Cost of services $ 2,055 $ 1,867 $ 188 10.1 % $ 6,024 $ 5,474 $ 550 10.1 % Selling, general and administrative 523 501 22 4.3…
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.